Trials / Completed
CompletedNCT03539549
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abicipar pegol | Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24. |
Timeline
- Start date
- 2018-05-25
- Primary completion
- 2019-02-27
- Completion
- 2019-02-27
- First posted
- 2018-05-29
- Last updated
- 2020-08-03
- Results posted
- 2020-08-03
Locations
37 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03539549. Inclusion in this directory is not an endorsement.